Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 7 , Pages 801-810 , July 2007

Factors Associated With Recruitment and Screening in the Treatment for Adolescents With Depression Study (TADS)

,Accepted 13 February 2007.

REFERENCES 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994;
  2. Baquet CR. Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev. 2006;30:24–33
  3. Bennett DS, Ambrosini PJ, Kudes D, Metz C, Rabinovich H. Gender differences in adolescent depression: do symptoms differ for boys and girls?. J Affect Disord. 2005;89:35–44
  4. Bjornson-Benson WM, Stibolt TB, Manske KA, Zavela KJ, Youtsey DJ, Buist AS. Monitoring recruitment effectiveness and cost in a clinical trial. Control Clin Trials. 1993;14:52–67
  5. Breland-Noble AM. Mental healthcare disparities affect treatment of black adolescents. Psychiatr Ann. 2004;34:534–541
  6. Breland-Noble AM, Bell CC, Nicolas G. Family first: the development of an evidence based family intervention for increasing participation in psychiatric clinical care and research in depressed African American adolescents. Fam Proc. 2006;45:153–169
  7. Diviak KR, Wahl SK, O'Keefe JJ, Mermelstein RJ, Flay BR. Recruitment and retention of adolescents in a smoking trajectory study: who participates and lessons learned. Subst Use Misuse. 2006;41:175–182
  8. Emslie GJ, Ryan ND, Wagner KD. Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. J Clin Psychiatry. 2005;66:14–20
  9. Emslie GJ, Wagner KD, Kutcher S. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2006;45:709–719
  10. Gorelick PB, Harris Y, Burnett B, Bonecutter FJ. The recruitment triangle: reasons why African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial. An interim report from the African-American Antiplatelet Stroke Prevention Study (AAASPS). J Natl Med Assoc. 1998;90:141–145
  11. Guy W. ECDEU Assessment Manual for Psychopharmacology. 2nd ed.. DHEW Publication ABM 76–388. Washington, DC: U.S. Government Printing Office; 1976;
  12. Hatcher S. Depression and randomized, controlled trials: problems and solutions. Expert Rev Neurother. 2006;6:41–462
  13. Hinshaw S, Hoagwood K, Jensen P, et al. AACAP 2001 research forum: challenges and recommendations regarding recruitment and retention of participants in research investigations. J Am Acad Child Adolesc Psychiatry. 2004;43:1037–1045
  14. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–988
  15. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602
  16. Miskimen T, Marin H, Escobar J. Psychopharmacological research ethics: special issues affecting US ethnic minorities. Psychopharmacology. 2003;171:98–104
  17. Mufson L, Dorta KP, Wickramaratne P, Nomura Y, Olfson M, Weissman MM. Randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry. 2004;61:577–584
  18. Olsson G. Adolescent depression: epidemiology, nosology, life stress and social network. Uppsala J Med Sci. 1998;103:77–145
  19. Poznanski EO Mokros HB. Children's Depression Rating Scale-Revised Manual. Los Angeles: Western Psychological Services; 1995;
  20. Rodriguez M, Rodriguez J, Davis M. Recruitment of first-generation Hispanics in a rural community: the essential nature of personal contact. Fam Proc. 2006;45:87–100
  21. SAS Institute . SAS System for Windows, version 9.1. Cary, NC: SAS Institute; 2004;
  22. Treatment for Adolescents With Depression Study (TADS) Team . Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 2003;42:531–542
  23. Treatment for Adolescents With Depression Study (TADS) Team . The Treatment for Adolescents With Depression Study (TADS): short-term effectiveness and safety outcomes. JAMA. 2004;292:807–820
  24. Treatment for Adolescents With Depression Study (TADS) Team . The Treatment for Adolescents With Depression Study (TADS): demographics and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2005;44:28–40
  25. Wagner KD, Jonas J, Findling RL, Ventura D, SaiKail K. Double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280–288
  26. Waller MW, Hallfors DD, Halpern CT, Iritani BJ, Ford CA, Guo G. Gender differences in associations between depressive symptoms and patterns of substance use and risky sexual behavior among a nationally representative sample of U.S. adolescents. Arch Womens Ment Health. 2006;9:139–150
  27. Yancey AK, Ortega AN, Kumanyika SK. Effective recruitment and retention of minority research participants. Annu Rev Public Health. 2006;27:1–28
  28. Zullino D, Conus P, Borgeat F, Bonsack C. Readiness to participate in psychiatric research. Can J Psychiatry. 2003;48:480–484

 Please see end of text for other author affiliations.The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the National Institute of Mental Health, the National Institutes of Health, or the Department of Health and Human Services.TADS is supported by contract N01 MH80008 from the National Institute of Mental Health to Duke University Medical Center (John S. March, Principal Investigator).Disclosure: Dr. Kratochvil has been a consultant or scientific advisor to Eli Lilly, Shire, Cephalon, Organon, AstraZeneca, Boehringer-Ingelheim, Abbott, and Pfizer; received research support from Abbott, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, and McNeil; served on the speaker's bureau of Eli Lilly; and received study drug for an NIMH-funded study from Lilly. Dr. Silva has been a consultant to Pfizer. Dr. Pathak has received research support from Forest Laboratories. Dr. Weller has been a consultant to and/or received research support from Otsuka, Johnson & Johnson, AstraZeneca, Organon, Pharma, Shire, and GlaxoSmithKline. Dr. March has been a consultant or scientific advisor to Pfizer, Eli Lilly, Wyeth, GlaxoSmithKline, Jazz, and MedAvante; has held stock in MedAvante; received research support from Eli Lilly; received study drug for an NIMH-funded study from Lilly and Pfizer; and is the author of the Multidimensional Anxiety Scale for Children (MASC). The other authors have no financial relationships to disclose.

PII: S0890-8567(09)62168-7

doi: 10.1097/CHI.0b013e3180582019

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 7 , Pages 801-810 , July 2007

Article Tools

* Image Usage & Resolution